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Abstract
Objectives: Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) has excellent cure rates and minimal side
effects. Despite the high burden of disease, strategies to ultimately eradicate HCV are being developed. However, the
delivery of care in regional settings is challenging and the efficacy of decentralised models of care is incompletely defined.
Methods: A prospective cohort study of patients whose treatment was initiated or supervised by Cairns Hospital, a tertiary
hospital which provides services to a culturally diverse population across a 380,748 km2 area in regional Australia. Patients‘
demographics, clinical features, DAA regimens and outcomes were recorded and correlated with their ensuing clinical
course.
Results: Over 22 months, 734 patients were prescribed DAA therapy for HCV. No patients were prescribed interferon.
Sofosbuvir/ledipasvir (n=371, 50.5%) and sofosbuvir/daclatasvir (n=287, 39.1%) were the most commonly prescribed
regimens. No patients ceased treatment due to adverse effects. There were 612/734 (83.4%) patients with complete
results, with 575 (94%) cured. At the end of the study period, there were 50 (6.8%) patients lost to follow-up and 72
(9.8%) awaiting SVR12 testing. The presence of cirrhosis (n=147/612, 24.1%) did not impact significantly on SVR12
rates, this being achieved in 136/147 (92.5%) cirrhotic patients versus 440/465 (94.6%) in non-cirrhotic patients (p=0.34).
Treatment-experienced patients (95/612, 18.3%) were more likely to be non-responders than treatment-naïve patients
(10/95 (10.5%) versus 26/517 (5%), p=0.04). Strategies to facilitate treatment included a dedicated clinical nurse consultant,
education to primary health care providers, specialist outreach clinics to regional communities and shared care with general
practitioners. SVR12 rates were similar amongst gastroenterologists (283/306, 92.5%), general practitioners (152/161,
94.4%), sexual health physicians (104/106, 98.1%) and other prescribers (37/39, 94.9%).
Conclusions: This study confirms that decentralised, multidisciplinary models of care can provide HCV treatment in regional
and remote settings with excellent outcomes.
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Introduction
Chronic hepatitis C virus infection (HCV) is a leading cause of
chronic liver disease and the commonest indication for liver
transplantation in Australia [1]. In 2015, there were 800 deaths
attributable to the disease in Australia, and it was estimated that
227,000 people were living with HCV; approximately 17,000 had
cirrhosis [2].
In Queensland, Australia‘s second-largest state, half the state‘s
population reside in regional areas and have limited access to both
primary and specialist care [3,4]. To eradicate HCV, health services
must overcome the challenges of delivering care to these regional
and remote areas, as this has previously limited HCV treatment
uptake [5].
The safety and efficacy of direct-acting antivirals (DAAs) has
heralded a new era of HCV treatment [6]. DAAs were subsidised
on the Pharmaceutical Benefit Scheme from March 2016,
facilitating access. Further barriers to treatment were removed
when the Pharmaceutical Benefits Advisory Committee
recommended that DAAs could be prescribed by any medical
practitioner experienced in treatment of HCV, or working in
consultation with an appropriate specialist or nurse practitioner
[7]. This had the potential to improve access to HCV treatment
in regional and remote centres significantly.
This study describes a decentralised model of DAA treatment
delivery to a culturally diverse population in a regional Australian
population with limited access to specialist care, and the associated
treatment outcomes.
Methods
This is a prospective cohort study of patients in regional Australia
with HCV infection and receiving treatment with DAAs between
1 February 2016 and 31 December 2017. Patients were identified
by referral to, or discussion with, the Cairns and Hinterland Hospital
and Health Service located in Far North Queensland, Australia.
Far North Queensland has a geographic area of 380,748 km2, and
a population of approximately 280,000, 9% of whom identify as
Aboriginal and/or Torres Strait Islanders [8].
Patient demographics (age, gender, indigenous status) were
collected to accurately describe the population characteristics.
Clinical data (HCV viral load, HCV genotype, presence of cirrhosis
and prior HCV treatment) were collected to analyse outcomes and
variables influencing differences in outcomes. The presence of
cirrhosis was determined by ultrasound or transient elastography
(defined as a value kPa ≥12.5).
Data were entered into an electronic database (Microsoft Excel,
Washington, USA) and analysed using statistical software (SPSS,
IBM Software, New York, USA). Differences between groups were
analysed using the chi-squared test.
Ethical approval for the study was provided by the Human
Research Ethics Committee of St Vincent‘s Hospital, Sydney. As
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the collected data were retrospective, aggregated and de-
identified, a requirement for patient consent was waived. The study
received no dedicated funding.
Model of care
Referrals were triaged by staff from the liver clinic, the sexual
health service or the addiction medicine service.
Patients with decompensated cirrhosis, prior treatment, significant
comorbidities or complex drug–drug interactions were seen in the
liver clinic. The sexual health and addiction medicine services and
general practitioners cared for their patients with uncomplicated
disease. The provision of treatment in regional settings was
facilitated through specialist visits to remote communities and the
delivery of DAAs to these areas by outreach pharmacy services.
A clinical nurse and sexual health physician visited the local prison
regularly to educate health workers and to assess and treat patients
[9]. Patient care was facilitated by having dedicated clinical nurses
or other staff collating required information or performing transient
elastography prior to the patient seeing a prescriber.
General practitioners‘ referrals of uncomplicated cases were
managed by providing the referring clinician with a standardised
document that provided guidance regarding the recommended
treatment regimen and monitoring. Additional phone or email
support was provided as required. Sessions to promote awareness
and provide education on hepatitis C treatment were provided to
primary health providers in an effort to increase the number of
potential prescribers. These education sessions were facilitated by
local gastroenterologists, general and sexual health physicians, and
supported by the Australasian Society for HIV, Viral Hepatitis and
Sexual Health Medicine (ASHM), as well as pharmaceutical
companies.
Promoting awareness has been a key priority in reaching and
treating patients with HCV. The Cairns Hospital Sexual Health
Service launched a campaign ‘Cairns Hep C Free by 2020’ and
has a local volunteer group called ‘CHAT’ (Cairns Hepatitis Action
Team) that promotes awareness of hepatitis C treatment in the
community. The campaign is staffed by two health promotion
officers who visit and provide education and promote awareness
to general practice clinics, needle exchange centres, addiction
medicine support groups and homeless shelters. Public awareness
has been further increased by advertising on highway billboards,
on public buses and in local newspapers.
Results
Over the 22-month study period, 734 consecutive patients were
prescribed DAAs for HCV.
Approximately half (49%) of the cohort had treatment prescribed
by general practitioners and non-gastroenterologist specialists
(Figure 1).
The most common genotypes were genotype 1a (340/734,
46.3%), genotype 3 (294/734, 40.1%) and genotype 1b (59/734,
8%) (Figure 2)
The most frequently prescribed DAA regimens were sofosbuvir/
ledipasvir (371/734, 50.5%), sofosbuvir/daclatasvir (287/734,
39.1%) and sofosbuvir/ribavirin (29/734, 4.0%) (Figure 3). No
patients were prescribed interferon. Other treatment regimens
included sofosbuvir/velpatasvir, elbasvir/grazoprevir, paritaprevir/
ritonavir/ombitasvir/dasabuvir, glecaprevir/pibrentasvir and
sofosbuvir/simeprevir. No patients ceased treatment due to adverse
effects.
The cohort was predominantly male (507/734, 69.1%) and the
mean age was 51.3 (range 19–77) years. Thirty-nine patients
(5.3%) identified as Aboriginal or Torres Strait Islander, while 1.6%
(12/734) of the cohort did not provide information on indigenous
status. Seventy-six patients (10.4%) were participating in an opioid
substitution programme and 34 (4.6%) patients had used injectable
drugs within the preceding 6 months; six (0.8%) patients had HIV
co-infection.
SVR12 results were available for 612 (83.4%) patients. These
patients had an SVR12 rate of 94%. Fifty patients (6.8%) were
lost to follow-up and 72 (9.8%) patients were awaiting SVR12
testing at the time of the study‘s completion (Figure 4).
Presence of cirrhosis (147/612, 24.1%) did not independently
impact significantly on SVR12 rates (136/147 [92.5%] vs 440/465
General physician
4%
Sexual Health
17%
Gastroenterologist
51%
General Practitioner
25%
ATODS
3%
Figure 1. Distribution of prescribers. ATODS: Alcohol, Tobacco and Other Dugs Service
GT 4
1% GT 5
0%
GT 3
40% GT 1a
46%
GT 2
5% GT 1b
8%
Figure 2. Distribution of genotype. GT: genotype
A decentralised model of care facilitates treatment of HCV in regional Australia 161
Journal of Virus Eradication 2018; 4: 160–164 ORIGINAL RESEARCH
[94.6%], p=0.34). Most cirrhotic patients were Child–Pugh A
(92.1%) rather than Child–Pugh B (7.3%) or Child–Pugh C (0.6%).
Treatment-experienced patients (95/612, 18.3% of the cohort)
were more likely to be non-responders compared to treatment-
naïve patients (10/95 [10.5%] vs 26/517 [5%], p=0.04) (Figure
5). The treatment-experienced patients included four patients who
had failed DAA therapy (4/95, 4.2%); three (75%) of these four
patients were non-responders to second-line DAA therapy.
Treatment outcomes were similar amongst gastroenterologists (SVR
283/306, 92.5%), general practitioners (SVR 152/161, 94.4%),
sexual health physicians (SVR 104/106, 98.1%) and other
prescribers (SVR 37/39, 94.9%).
Discussion
This study demonstrates that HCV can be treated in a regional
setting by non-specialist physicians with outcomes equivalent to
those from published clinical trials [10], with limited additional
resources and funding. The multidisciplinary, decentralised
approach used in this cohort was able to reach vulnerable
populations in one of the most remote regions of Australia. This
approach would be expected to decrease HCV-related morbidity
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Figure 3. Direct-acting antiviral regimen prescriptions. SOF/LDV: sofosbuvir/
ledipasvir; SOF/DAC: sofosbuvir/daclatasvir; SOF/RBV: sofosbuvir/ribavirin;
SOF/VEL: sofosbuvir/velpatasvir
Figure 4. Patient prescriptions and outcomes. DAAs: direct-acting antivirals; SVR: sustained virological response at 12 weeks
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Figure 5. Rates (%) of sustained virological response at 12 weeks
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and mortality and reduce transmission, increasing the likelihood
of HCV elimination [7,11].
The health service used several strategies to decentralise treatment
to increase DAA uptake. Specific models of care provided access
to treatment for marginalised populations, including persons who
inject drugs and persons in correctional facilities, in a culturally
appropriate manner. The fact that the patients‘ existing health
care workers were able to prescribe the DAA therapy permitted
prescription of DAA therapy within an existing therapeutic
relationship, improving engagement and treatment adherence
[12,13].
The current study demonstrates that with appropriate education
and support, primary care providers can treat the vast majority
of patients eligible for direct-acting antivirals and play an integral
role in HCV treatment. Their role is likely to increase with the
simplicity of new pan-genotypic regimens with shorter lengths
of treatment. Primary care providers were empowered through
education programmes and shared-care models to prescribe
community-based treatment, enhancing their skill mix and job
satisfaction [14]. An additional benefit is that these providers,
through their long-term involvement with the patients, are better
able to manage other major comorbidities – including alcohol
consumption and obesity – which affect liver and general health
as much as, if not more than, HCV [15]. Competent primary care
prescribers also minimise the need for specialist referral, which can
interrupt the cascade of care and delay therapy, and can also
disadvantage patients averse to attending hospitals. These
collaborative and multidisciplinary approaches are critical to
achieving the goal of HCV elimination and are recognised in federal
and state government strategies [16,17], as well as other recently
published real-world examples [18]. They can foster collaborative
care amongst clinicians and may be a model for other medical
conditions or health issues [19].
Dedicated nurse practitioners and clinical nurses can play an
integral role with triaging, assessing, educating and coordinating
DAA treatment of patients with HCV, thereby increasing the
accessibility and throughput of services [4,7]. Although our model
did not allow for nurse prescribers, this strategy has been used
elsewhere in treatment of HCV with similar cure rates to medical
officers [19].
Further specialist care was expanded by increasing tertiary clinic
throughput in hospital clinic settings, and the delivery of specialist
care to remote areas via outreach visits in a ‘hub and spoke’
manner [3]. Gastroenterologist and other specialist-led treatment
will continue to be important in managing patients with HCV who
have cirrhosis, are treatment experienced, or who have complex
care needs. However, this type of service does not have the
capacity to treat every patient with HCV, particularly in remote
centres. A decentralised model is necessary to ensure that all
patients have access to this very safe, effective and well tolerated
DAA therapy.
The experience from this study is in keeping with the growing
body of evidence surrounding models of care for HCV treatment,
and other health care in rural and remote Australia. These include
integrated/shared-care models between specialists and general
practitioners, outreach services (hub and spoke type delivery with
periodic visiting specialists), use of telehealth services, nurse
practitioner models and educational programmes [5,20,21]. By
using these strategies, this study‘s outcomes of HCV treatment
are consistent with the high benchmark set in clinical trials and
confirmed in recently published real-world experience [10,22,23].
There are several weaknesses in this study. Data collection was
incomplete, particularly because not all patients treated by general
practitioners independent of Cairns and Hinterland Hospital and
Health Service may have been captured. Even so, this study has
demonstrated that a significant number of patients have been
treated in primary care with excellent outcomes.
Strengths of this study include its prospective design, with relatively
large and consecutive numbers capturing data from multiple
models of care. Furthermore, although the North Queensland
population is a relatively mobile one, we were able to access the
vast majority of patient data.
Future studies might examine treatment strategies to access
individuals who are continuing to transmit the infection, particularly
those who continue to inject drugs. Although not captured in this
study, data detailing country of birth and ethnicity could provide
insights into the local epidemiology of the infection and the
individuals who are and, as significantly, who are not accessing
treatment. This might inform specific culturally appropriate
strategies to reach these populations. It will be interesting to see
whether similar or even better results can be achieved with new
shorter regimens. It will also be important to optimise the therapy
of patients who have failed DAA treatment, and special populations
such as persons with chronic kidney disease [24].
In conclusion, non-specialist prescribers can effectively and quickly
treat large numbers of patients using a decentralised,
multidisciplinary model of care that reaches geographically isolated,
socially marginalised and other vulnerable patient populations. This
has the potential to significantly reduce the burden of HCV-related
disease and is an excellent model for other chronic health
conditions affecting these populations.
Acknowledgements
We are grateful to A/Prof Gail Matthews, Prof Greg Dore, Pip
Marks and Jasmine Yee from the Kirby Institute for their support.
We acknowledge the many clinicians from the Cairns Hospital
involved in delivering this model of care including Dr Geogry Peter
Kini, Dr John Ombiga, Dr Trent Yarwood and Dr Simon Smith.
Declaration of interests
The authors have no declarations of interest.
Funding
The study received no dedicated funding.
References
1. McCaughan GW, Munn SR. Liver transplantation in Australia and New Zealand. Liver
Transpl 2016; 22: 830–838.
2. Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia
Annual Surveillance Report 2016. Sydney: UNSW Australia; 2016. Available at:
https://kirby.unsw.edu.au/report/annual-surveillance-report-hiv-viral-hepatitis-
stis-2016 (accessed June 2018).
3. Wakerman J, Humphreys JS, Wells R et al. Primary health care delivery models in
rural and remote Australia: a systematic review. BMC Health Serv Res 2008; 8: 276.
4. Keogh K, Clark P, Valery PC et al. Use of telehealth to treat and manage chronic
viral hepatitis in regional Queensland. J Telemed Telecare 2016; 22: 459–464.
5. Cheng W, Nazareth S, Flexman JP. Statewide hepatitis C model of care for rural
and remote regions. J Gastroenterol Hepatol 2015; 30 Suppl 2: 1–5.
6. Manns MP, Buti M, Gane E et al. Hepatitis C virus infection. Nat Rev Dis Primers
2017; 3: 17006.
7. Hepatitis C Virus Infection Consensus Statement Working Group. Australian
recommendations for the management of hepatitis C virus infection: a consensus
statement (August 2017). Melbourne: Gastroenterological Society of Australia; 2017.
Available at: www.hepcguidelines.org.au (accessed June 2018).
8. Australian Bureau of Statistics. Population distribution, Aboriginal and Torres Strait
Islander Australians (cat. no. 4705.0). Australia: 2007. Available at: www.abs.gov.au/
ausstats/abs@.nsf/mf/4705.0 (accessed June 2018).
9. Bartlett SR, Fox P, Cabatingan H et al. Demonstration of near-elimination of hepatitis
C virus among a prison population: the Lotus Glen Correctional Centre hepatitis C
treatment project. Clin Infect Dis 2018.
10. Younossi ZM, Park H, Gordon SC et al. Real-world outcomes of ledipasvir/sofosbuvir
in treatment-naive patients with hepatitis C. Am J Manag Care 2016; 22: SP205–211.
A decentralised model of care facilitates treatment of HCV in regional Australia 163
Journal of Virus Eradication 2018; 4: 160–164 ORIGINAL RESEARCH
11. Backus LI, Belperio PS, Shahoumian TA, Mole LA. Direct-acting antiviral sustained
virologic response: impact on mortality in patients without advanced liver disease.
Hepatology 2018.
12. Read P, Lothian R, Chronister K et al. Delivering direct acting antiviral therapy for
hepatitis C to highly marginalised and current drug injecting populations in a targeted
primary health care setting. Int J Drug Policy 2017.
13. Scott N, Iser DM, Thompson AJ et al. Cost-effectiveness of treating chronic hepatitis
C virus with direct-acting antivirals in people who inject drugs in Australia. J
Gastroenterol Hepatol 2016; 31: 872–882.
14. Lambert SM, Page AN, Wittmann J et al. General practitioner attitudes to prescribing
hepatitis C antiviral therapy in a community setting. Aust J Prim Health 2011; 17:
282–287.
15. Innes H, McAuley A, Alavi M et al. The contribution of health risk behaviors to excess
mortality in American adults with chronic hepatitis C: A population cohort-study.
Hepatology 2018; 67: 97–107.
16. Australian Government Department of Health. Fourth National Hepatitis C Strategy
2014–2017. Canberra: Commonwealth of Australia; 2014. Available at:
www.health.gov.au/internet/main/publishing.nsf/content/ohp-bbvs-hepc (accessed
June 2018).
17. Queensland Health. Queensland Hepatitis C Action Plan 2016–2021. Brisbane: State
of Queensland (Queensland Health); 2016. Available at: www.health.qld.gov.au/
__data/assets/pdf_file/0024/601890/qh-hepc-action-plan.pdf (accessed June
2018).
18. Capileno YA, Van den Bergh R, Donchunk D et al. Management of chronic hepatitis
C at a primary health clinic in the high-burden context of Karachi, Pakistan. PLoS
One 2017; 12: e0175562.
19. Kattakuzhy S, Gross C, Emmanuel B et al. Expansion of treatment for hepatitis C
virus infection by task shifting to community-based nonspecialist providers: a
nonrandomized clinical trial. Ann Intern Med 2017; 167: 311–318.
20. Arora S, Thornton K, Murata G et al. Outcomes of treatment for hepatitis C virus
infection by primary care providers. N Engl J Med 2011; 364: 2199–2207.
21. Nazareth S, Kontorinis N, Muwanwella N et al. Successful treatment of patients
with hepatitis C in rural and remote Western Australia via telehealth. J Telemed
Telecare 2013; 19: 101–106.
22. Bhattacharya D, Belperio PS, Shahoumian TA et al. Effectiveness of all-oral antiviral
regimens in 996 human immunodeficiency virus/hepatitis C virus genotype
1-coinfected patients treated in routine practice. Clin Infect Dis 2017; 64: 1711–1720.
23. Wu CJ, Roytman MM, Hong LK et al. Real-world experience with sofosbuvir-based
regimens for chronic hepatitis C, including patients with factors previously associated
with inferior treatment response. Hawaii J Med Public Health 2015; 74: 3–7.
24. Andreoni M, Babudieri S, Bruno S et al. Current and future challenges in HCV: insights
from an Italian experts panel. Infection 2018; 46: 147–163.
ORIGINAL RESEARCH Journal of Virus Eradication 2018; 4: 160–164
164 A Lee et al.
